<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03658850</url>
  </required_header>
  <id_info>
    <org_study_id>2.603.927</org_study_id>
    <nct_id>NCT03658850</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Hydrochlorothiazide in the Treatment of Hypernatremia in Critically Ill Patients</brief_title>
  <acronym>HYDRA</acronym>
  <official_title>Safety and Efficacy of Hydrochlorothiazide in the Treatment of Hypernatremia in Critically Ill Patients: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      HYDRA is a randomized clinical trial designed to evaluate safety and efficiency of
      hydrochlorothiazide in critical patients with hypernatremia
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">March 10, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 10, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hypernatremia correction</measure>
    <time_frame>DAY 3</time_frame>
    <description>proportion of patients with hypernatremia correction (serum sodium below 145 mEq / L) at the end of Day 3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>renal replacement therapy</measure>
    <time_frame>6 months</time_frame>
    <description>need to renal replacement therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mechanical ventilation</measure>
    <time_frame>6 months</time_frame>
    <description>incidence of mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vasoactive drugs</measure>
    <time_frame>6 months</time_frame>
    <description>need for vasoactive drugs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>6 months</time_frame>
    <description>hospital mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serious adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>incidence of serious adverse events 37/5000 incidence of serious adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">184</enrollment>
  <condition>Hypernatremia</condition>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the experimental group will receive one tablet of hydrochlorothiazide in the presentation of 50mg or equivalent enteral solution every 12h (total of 100mg per day) enterally for 3 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo group will receive one tablet or equivalent volume of enteral solution of inert substance</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide 50Mg</intervention_name>
    <description>for the experimental group received a hydrochlorothiazide tablet on presentation of 50mg or equivalent enteral solution every 12h (total of 100mg per day) enterally on day 0 (D0) until day 3</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>for the placebo group will receive one tablet or equivalent volume of enteral solution of inert substance, identical to the hydrochlorothiazide presentations, every 12 hours until day 3</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  hospitalized for intensive care,

          -  Over 18 years of age,

          -  Two serum sodium measurements above 145 mEq / L (with no pre-determined interval
             between them),

          -  Mean arterial pressure greater than 65mmHg

        Exclusion Criteria:

          -  Absence of consent to participate in the study

          -  Cardiac index below 2.5L / min / m2 OR signs of ineffective circulation (capillary
             filling time greater than 2 seconds, cold or sticky skin) OR arterial lactate&gt; 4mMol /
             L.

          -  Use of vasopressors at doses greater than 0.1 mcg / kg / min of noradrenaline or with
             initiation or increase of dose within less than one hour before inclusion in the
             study.

          -  Unavailable enteral route.

          -  Use of hydrochlorothiazide in the last 7 days of ICU admission.

          -  History of allergy or intolerance to hydrochlorothiazide or other thiazides.

          -  Nephrogenic Diabetes Insipidus.

          -  Renal impairment KDIGO 3

          -  Indication of renal replacement therapy.

          -  Acute neurological insult.

          -  Heart failure American Heart Association classification (AHA), class D.

          -  Liver cirrhosis Child-Pugh C.

          -  Pregnant women

          -  Exclusive palliative care

          -  Dying, with expected survival less than 48 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>André LN Gobatto, p.h.d</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>André LN Gobatto, p.h.d</last_name>
    <phone>+5571988646501</phone>
    <email>andregobatto@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>André LN Gobatto, M.D.</last_name>
      <phone>+5511991796501</phone>
      <email>andregobatto@gmail.com</email>
    </contact>
    <investigator>
      <last_name>André LN Gobatto, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>May 22, 2018</study_first_submitted>
  <study_first_submitted_qc>September 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2018</study_first_posted>
  <last_update_submitted>April 27, 2019</last_update_submitted>
  <last_update_submitted_qc>April 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>André Luiz Nunes Gobatto</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>hypernatremia</keyword>
  <keyword>Critical care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypernatremia</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

